Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.

Nature communications - 26 Sept 2022

East Philip, Kelly Gavin P, Biswas Dhruva, Marani Michela, Hancock David C, Creasy Todd, Sachsenmeier Kris, Swanton Charles, Downward Julian, de Carné Trécesson Sophie

Abstract excerpt

Activating mutations in KRAS occur in 32% of lung adenocarcinomas (LUAD). Despite leading to aggressive disease and resistance to therapy in preclinical studies, the KRAS mutation does not predict patient outcome or response to treatment, presumably due to additional events modulating RAS pathways. To obtain a broader measure of RAS pathway activation, we developed RAS84, a transcriptional signature optimised to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to RNA modifications and cancer

Source

Open in PubMed Open full text

Identifiers

PMID: 36163168
DOI: 10.1038/s41467-022-33290-0
PMCID: PMC9512813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.PMID 36163168Read ↗

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinomaSemantic proximity Read ↗

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.Semantic proximity Read ↗

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read ↗

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinomaSemantic proximity Read ↗

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Lung Adenocarcinoma Just Desserts: An Expanding Pie of Activating Oncogenes or a Layer Cake of Integrated AlterationsSemantic proximity Read ↗

Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.Semantic proximity Read ↗

RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.Semantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.